Edition:
United States

Independent data monitoring committee recommends discontinuation of the phase 2b strive clinical trial of staphylococcus aureus vaccine following planned interim analysis


Thursday, 20 Dec 2018 04:30pm EST 

Dec 20 (Reuters) - Pfizer Inc ::INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS DISCONTINUATION OF THE PHASE 2B STRIVE CLINICAL TRIAL OF STAPHYLOCOCCUS AUREUS VACCINE FOLLOWING PLANNED INTERIM ANALYSIS.INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS DISCONTINUATION OF THE PHASE 2B STRIVE CLINICAL TRIAL OF STAPHYLOCOCCUS AUREUS VACCINE FOLLOWING PLANNED INTERIM ANALYSIS.PFIZER - DMC CONCLUDED STUDY REACHED FUTILITY.PFIZER INC - SAFETY REVIEW BY DMC INDICATED THAT INVESTIGATIONAL VACCINE HAS BEEN SAFE AND WELL TOLERATED.PFIZER INC - STRIVE TRIAL PARTICIPANTS WHO ARE ENROLLED IN STUDY WILL COMPLETE STUDY'S FOLLOW-UP EVALUATIONS.PFIZER INC - EVALUATING NEXT STEPS FOR POTENTIAL DEVELOPMENT OF A S. AUREUS VACCINE.